Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and cell death
Z. Kabakci, S. Kaeppeli, G. Cozza, C. Cantu, C. Koenig, J. Toggweiler, C. Gentili, G. Ribaudo, G. Zagotto, K. Basler, L. A. Pinna, S. Ferrari
Abstract
CDC25 phosphatases have a key role in cell cycle transitions and are important targets for cancer therapy. Here, we set out to discover novel CDC25 inhibitors. Using a combination of computational approaches we defined a minimal common pharmacophore in established CDC25 inhibitors and performed a virtual screening of a proprietary library. Taking advantage of the availability of crystal structures for CDC25A and CDC25B and using a molecular docking strategy, we carried out hit expansion/optimization. Enzymatic assays revealed that naphthoquinone scaffolds were the most promising CDC25 inhibitors among selected hits. At the molecular level, the compounds acted through a mixed-type mechanism of inhibition of phosphatase activity, involving reversible oxidation of cysteine residues. In 2D cell cultures, the compounds caused arrest of the cell cycle at the G1/S or at the G2/M transition. Mitotic markers analysis and time-lapse microscopy confirmed that CDK1 activity was impaired and that mitotic arrest was followed by death. Finally, studies on 3D organoids derived from intestinal crypt stem cells of Apc/K-Ras mice revealed that the compounds caused arrest of proliferation.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cryo-EM structure of the CDK2-cyclin A-CDC25A complex
R. J. Rowland, S. Korolchuk, … J. A. Endicott·bioRxiv·Oct 17, 2023
- Identification and Validation of Novel Microtubule Suppressors with an Imidazopyridine Scaffold through Structure Based Virtual Screening and Docking.
S. A. Elseginy, A. S. F. Oliveira, … R. B. Sessions·bioRxiv·Dec 8, 2021
- Computational Repurposing of FDA Approved Drugs Against Cyclin Dependent Kinase (CDK2)
Girija Deevi, Bhupender Singh·bioRxiv·Nov 1, 2026
- A Robust Computational Framework for the Optimization of CDK7 Inhibitors as Promising Cancer Therapy
Zhaoqi Shi, Xufan Gao, … Ruhong Zhou·The Journal of Physical Chemistry BPeer-reviewed·Aug 19, 2025
- Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
B. R. Pennycook, A. R. Barr·bioRxiv·May 6, 2021
- Podophyllotoxin And Quercetin In Silico Derivatives Docking Analysis With Cyclooxygenase-2 And Aminopeptidase-N
A.E. Manukyan, Ashkhen A. Hovhannisyan·bioRxiv·Feb 26, 2021